Contributors
Christopher E. Andoniou(Lions Eye Institute), Akira Komoriya(OncoImmune (United States)), Heike E. Daldrup‐Link(Lucile Packard Children's Hospital), Taisuke Ito, Guido Ferlazzo(University of Messina), Angela Gismondi(Roma Tre University), William L. Camp(University of Pittsburgh), Paolo Carrega(University of Messina), Godfrey S. Getz(University of Chicago), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rolf Kiessling(Unknown), Alex Karlsson‐Parra(Uppsala University Hospital), Mariapia A. Degli‐Esposti(Lions Eye Institute), Segundo González, Vasileios Bekiaris(Technical University of Denmark), Stephen R. Goding(University of Maryland, Baltimore), Kym R. Garrod, Lesley R. de Armas, Petter Höglund(Karolinska University Hospital), Bartosz Grzywacz(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Veli‐Matti Kähäri(University of Turku), Priyanka Jha(Santosh University), Giovanni Bernardini(University of Insubria), Anne Hosmalin(Centre National de la Recherche Scientifique), Edward L. Briercheck(The Ohio State University), Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Cyril Fauriat(Centre National de la Recherche Scientifique), Aharon G. Freud(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Franck Housseau(Centre National de la Recherche Scientifique), Anna Balato(University of Campania "Luigi Vanvitelli"), Michael D. Cahalan(University of California, Irvine), Tatsuya Kanto(National Center for Global Health and Medicine), P.K. Epling-Burnette, Shinichi Koizumi, Régis Costello(Inserm), Anthony A. Gaspari(Thomas Jefferson University), Benedict J. Chambers(Karolinska Institutet), Jérôme D. Coudert(The University of Western Australia), Per Basse(Roswell Park Comprehensive Cancer Center), Martin R. Goodier, Maryanne A. Bryan(University of Pittsburgh), Christiane Knopp, James R. Carlyle(Sunnybrook Health Science Centre), Jia Fan(Nanjing Tech University), Sarah Cooley(Palmetto Hematology Oncology), Takayuki Ikeda(University of California, San Francisco), Hans Klingemann(Tufts Medical Center), Kenji Chamoto(Kyoto University), Julie Y. Djeu, Claudia Carlino(Istituto Pasteur)
Cited by 0
Related Papers
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
|Nature|1986|2.1k
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
|Proceedings of the National Academy of Sciences|2012|1.5k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k